2.1100
+0.1800
+(9.33%)
At close: January 10 at 4:00:02 PM EST
2.2100
+0.10
+(4.74%)
After hours: January 10 at 5:58:33 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
29,617.0000
15,348.0000
27,647.0000
26,605.0000
20,496.0000
Operating Income
-29,617.0000
-15,348.0000
-27,647.0000
-26,605.0000
-20,496.0000
Net Non Operating Interest Income Expense
--
400.0000
300.0000
--
--
Other Income Expense
32.0000
-728.0000
318.0000
441.0000
-700.0000
Pretax Income
-29,185.0000
-15,676.0000
-27,329.0000
-26,164.0000
-21,196.0000
Net Income Common Stockholders
-29,241.0000
-15,732.0000
-27,329.0000
-26,164.0000
-21,157.0000
Diluted NI Available to Com Stockholders
-29,241.0000
-15,732.0000
-27,329.0000
-26,164.0000
-21,157.0000
Basic EPS
-2.88
-3.42
-6.02
-5.89
-12.20
Diluted EPS
-2.88
-3.42
-6.02
-5.89
-12.20
Basic Average Shares
13,708.4440
4,598.7150
4,539.3180
4,440.3380
1,743.3340
Diluted Average Shares
13,708.4440
4,598.7150
4,539.3180
4,440.3380
1,743.3340
Total Operating Income as Reported
-29,605.0000
-16,276.0000
-27,647.0000
-26,605.0000
-20,496.0000
Total Expenses
29,617.0000
15,348.0000
27,647.0000
26,605.0000
20,496.0000
Net Income from Continuing & Discontinued Operation
-29,241.0000
-15,732.0000
-27,329.0000
-26,164.0000
-21,157.0000
Normalized Income
-29,453.0000
-15,004.0000
-27,329.0000
-26,164.0000
-21,257.0000
Interest Income
--
400.0000
300.0000
--
--
Net Interest Income
--
400.0000
300.0000
--
--
EBIT
-29,617.0000
-15,348.0000
-27,647.0000
-26,605.0000
-20,496.0000
EBITDA
-29,502.0000
-15,229.0000
-27,478.0000
-26,484.0000
-20,333.0000
Reconciled Depreciation
115.0000
119.0000
169.0000
121.0000
163.0000
Net Income from Continuing Operation Net Minority Interest
-29,241.0000
-15,732.0000
-27,329.0000
-26,164.0000
-21,157.0000
Total Unusual Items Excluding Goodwill
212.0000
-728.0000
--
400.0000
100.0000
Total Unusual Items
212.0000
-728.0000
--
400.0000
100.0000
Normalized EBITDA
-29,714.0000
-14,501.0000
-27,478.0000
-26,484.0000
-20,433.0000
12/31/2020 - 6/29/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ACTU Actuate Therapeutics, Inc. Common stock
8.30
+3.75%
INAB IN8bio, Inc.
0.3233
+3.42%
RLMD Relmada Therapeutics, Inc.
0.4124
-8.76%
AIM AIM ImmunoTech Inc.
0.2150
-0.92%
CUE Cue Biopharma, Inc.
1.5100
+4.14%
APTO Aptose Biosciences Inc.
0.2200
+3.19%
COYA Coya Therapeutics, Inc.
5.77
-4.94%
OVID Ovid Therapeutics Inc.
0.8207
-9.80%
AKTX Akari Therapeutics, Plc
1.2150
-5.08%
IMMP Immutep Limited
2.0100
+0.50%